Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06686693 · ClinicalTrials.gov registry record · Phase 4

Intravenous Iron Effects on Performance at High Altitude

A Phase 4 study of Hypoxia, sponsored by United States Army Research Institute of Environmental Medicine.

Recruiting
Registry status
Phase 4
Development phase
24
Enrollment target
1
Study location

NCT06686693: Recruiting Phase 4 study of Hypoxia, sponsored by United States Army Research Institute of Environmental Medicine.

NCT06686693 is a Phase 4 study of Hypoxia that is actively recruiting participants, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 24 participants, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06686693, a Phase 4 study of Hypoxia, is actively recruiting participants, sponsored by United States Army Research Institute of Environmental Medicine.

RECRUITING
Registry status
Phase 4
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

To compare the effects of IV iron versus placebo (saline) injection on arterial oxygen saturation, submaximal exercise responses, and 2-mile treadmill time-trial performance during acute exposure to hypobaric hypoxia (430 mmHg, simulating \~4800m) assessed 1 and 14 days after treatment. Primary Hypothesis 1: IV iron treatment will improve arterial oxygen saturation at rest and during exercise in acute hypobaric hypoxia and this effect will persist for 2 weeks Primary Hypothesis 2) IV iron treatment will improve 2-mile treadmill time trial performance in acute hypobaric hypoxia and this effect will persist for 2 weeks

Primary Outcome

Time to complete self-paced 2 miles treadmill time trial (min:sec)

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Injectafer

Study Locations (1)

Massachusetts

  • USARIEM - Natick

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-04-15
Est. Completion 2025-09-30
Phase Phase 4

What NCT06686693 shows while recruiting

NCT06686693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hypoxia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06686693 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06686693 about?

NCT06686693 is a clinical study titled "Intravenous Iron Effects on Performance at High Altitude". To compare the effects of IV iron versus placebo (saline) injection on arterial oxygen saturation, submaximal exercise responses, and 2-mile treadmill time-trial performance during acute exposure to hypobaric hypoxia (430 mmHg, simulating \~4800m) assessed 1 and 14 days after treatment. Primary Hyp...

What is the current status of trial NCT06686693?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2022-04-15. Estimated completion is 2025-09-30.

What conditions does trial NCT06686693 study?

This clinical trial studies the following conditions: Hypoxia.

What interventions are being tested in trial NCT06686693?

The interventions under investigation include: Placebo (OTHER), Injectafer (DRUG).

Who is sponsoring clinical trial NCT06686693?

This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06686693 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypoxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06686693's enrollment target sits among peer trials

24 24th of 39 higher than 16 of 39 other Hypoxia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypoxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06686693, the US trial registry maintained by the National Library of Medicine. NCT06686693 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.